header
Image from OpenLibrary

Immunological study on the neutralizing activity of anti-E₁ monoclonal antibodies against hepatitis C virus / Rehab Ibrahim Mohamed Moustafa ; Supervised Hussein A. Shoeb , Manal M. Hussein , Mostafa K. Alawady

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Rehab Ibrahim Mohamed Moustafa , 2010Description: 135 P. : charts ; 25cmOther title:
  • لفيروس الكبد الوبائي سي E1 دراسة مناعية لتقييم فعالية الأجسام المضادة وحيدة النسيلة الموجهة ضد منطقة الغلاف الأول [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Microbiology and Immunology Summary: The current treatment of HCV, consisting of pegylated interferon-Ü alone or in combination with ribavirin, is unsuccessful in more than half of the subjects infected with HCV genotype 1 and 4. Due to the expensiveness of the treatment and its association with frequent side effects, new therapies for chronic HCV are surgently needed as well as a prophylactic vaccine
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.06.M.Sc.2010.Re.I (Browse shelf(Opens below)) Not for loan 01010110053977000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.06.M.Sc.2010.Re.I (Browse shelf(Opens below)) 53977.CD Not for loan 01020110053977000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Microbiology and Immunology

The current treatment of HCV, consisting of pegylated interferon-Ü alone or in combination with ribavirin, is unsuccessful in more than half of the subjects infected with HCV genotype 1 and 4. Due to the expensiveness of the treatment and its association with frequent side effects, new therapies for chronic HCV are surgently needed as well as a prophylactic vaccine

Issued also as CD

There are no comments on this title.

to post a comment.